Forewarned is forearmed

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 626-627

  Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

DISEASE COURSE; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; FIBROSIS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 70249091405     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.06.010     Document Type: Editorial

References (19)

1. Seeff L.B. The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1 (1997) 587-602
2. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N Engl J Med 345 (2001) 41-52
3. Zeuzem S., Teuber G., Lee J.H., Rüster B., and Roth W.K. Risk factors for the transmission of hepatitis C. J Hepatol 24 (1996) S3-S10
4. Bochud P.-Y., Cai T., Overbeck K., Bochud M., Dufour J.-F., Müllhaupt B., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 51 (2009) 655-666
5. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
6. Adinolfi L.E., Gambardella M., Andreana A., Tripodi M.F., Utili R., and Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358-1364
7. Andriulli A., Mangia A., Iacobellis A., Ippolito A., Leandro G., and Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 28 (2008) 397-404
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
9. Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Solá R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 (2007) 124-134
10. Zeuzem S., Hultcrantz R., Bourliere M., Goeser T., Marcellin P., Sanchez-Tapias J., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40 (2004) 993-999 Erratum in: J Hepatol 2005;42:434
11. Willems B., Hadziyannis S.J., Morgan T.R., Diago M., Marcellin P., Bernstein D., et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response?. J Hepatol 46 (2007) S6
12. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009) 1827-1838
13. Hézode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009) 1839-1850
14. TM (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J Hepatol 50 (2009) S4
15. Foster G.R., Hezode C., Bronowicki J.-P., Carosi G., Weiland O., Verlinden L., et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209. J Hepatol 50 (2009) S22
16. Benhamou Y., Moussalli J., Ratziu V., Lebray P., Gysen V., de Backer K., et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 HCV patients. J Hepatol 50 (2009) S6
17. Soriano V., Peters M.G., and Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 48 (2009) 313-320
18. Gane E.J., Rodriguez-Torres M., Nelson D.R., Jacobson I.M., McHutchison J.G., Jeffers L., et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500 mg bid with PEG-IFN and ribavirin for 28 days. Hepatology 48 (2008) 1024A
19. Flisiak R., Feinman S.V., Jablkowski M., Horban A., Kryczka W., Pawlowska M., et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-nai{dotless}̈ve hepatitis C patients. Hepatology 49 (2009) 1460-1468